1. Generics Bulletin
  2. >>Business
  3. >>Deals

Formycon Signs APAC Eylea Biosimilar Deal With Taiwan’s Lotus

The Aflibercept Deal Follows A Flurry Of Approvals In The Past Year

 
• By Adam Zamecnik

Having secured approvals for the Eylea biosimilar in major markets such as the US and Europe, Formycon has signed a fresh licensing deal with Lotus Pharmaceutical, giving away rights to the asset in the APAC region.

APAC
join Scrip's APAC regional team for a video overview of recent industry topics and trends • Source: Shutterstock

Formycon and its licensing partner Klinge have signed a deal with Taiwan-headquartered player Lotus Pharmaceutical for commercialization rights to Formycon’s Eylea (aflibercept) biosimilar FYB203 in multiple countries in the Asia-Pacific region.

Signed for an undisclosed sum, the deal will hand over commercialization rights to Lotus in countries such as Indonesia, Malaysia and the Philippines. The agreement will also enable Lotus to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Generics Bulletin

Formycon Hopes Stelara Biosimilar Sales To Pull Through FY2025 As Q1 Revenues Slump

 
• By Urtė Fultinavičiūtė

Formycon said it predicted low earnings in the first quarter of 2025, after enjoying milestone payments last year. Now, the pressure is on the growing biosimilars portfolio to pull the company through this year.

Gedeon Richter Feels Biosimilar Model ‘Is Looking For An Equilibrium’

 
• By Dean Rudge

Gedeon Richter’s CEO weighed in on the pricing landscape for biosimilars as the firm admitted the market for biosimilar denosumab was set to be more crowded than it had initially anticipated.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.